By using K-RAS mutated pancreatic cell lines genetically engineered to express high or low levels of Gal-3, they demonstrated that down regulation of Gal-3 decreased PDAC cell proliferation and invasion in vitro and reduced tumor volume in a mouse model. This evidence concerns the gene KRAS and neoplasm.